The document discusses how brands can apply a brand-led health claims strategy in light of EFSA's negative rulings on health claims. It notes that EFSA's rulings have made companies realize they have neglected their most important asset - their brand. It recommends understanding where the brand fits in the health and wellness landscape, and which type of stakeholders it can target, in order to determine the right health claims strategy without undermining the brand.
Healthcare Professionals' Social Networks: The Beginning of the End of Pharma...Len Starnes
First presented at Digital Pharma Europe, Barcelona, 31st March 2009.
Captures the current status of healthcare professionals' social networks from a global perspective and a pharmaceutical industry marketing & sales perspective
Healthcare Professionals' Social Networks: The Beginning of the End of Pharma...Len Starnes
First presented at Digital Pharma Europe, Barcelona, 31st March 2009.
Captures the current status of healthcare professionals' social networks from a global perspective and a pharmaceutical industry marketing & sales perspective
Taking the Red Pill - How Can OTC Drug Brands Penetrate More HouseholdsTwentify
A look at the Canadian OTC drugs market, and examples on how market research can help brands in this market on differentiating themselves to get ahead of the competition.
How can OTC drug brands get ahead of the competition and differentiate themselves in the market using market research?
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...Eularis
After years of relatively easy blockbuster profits, worldwide respect and investment, and loyal customer bases, branded pharmaceutical companies are in trouble, increasingly vulnerable to the threats posed by the competition.
And who is that competition? It’s not other branded companies any more. Generics have emerged as the primary challenger to pharmaceutical industry success, offering a public hungry for medications and reduced costs exactly what they want and need. Generics have exploded in the last decades, and are poised for even bigger growth.
The situation is grim. It can seem like pharmaceutical companies have no recourse in the face of the lower prices and operating costs of the generics industry, and fortunes will only continue to fade.
But options do exist for pharmaceutical companies to mount an effective defense strategy against the threats posed by generics.
In this report, we examine some of these defensive strategies. We analyze the environment for pharmaceuticals today, as well as the generic industry as a whole.
We describe the pros and cons of legal defensive strategies, as well as opportunities to expand the revenue-generating product life cycle into reformulations and over-the-counter medications.
We look at pricing strategies, as well as company organizational changes as part of an integrated defense strategy.
And to help companies make tough decisions about the best defense, we examine powerful analytics techniques and case studies.
Object Relational Mapping with LINQ To SQLShahriar Hyder
OR Impedance Mismatch
Object Relational Mapping
The LINQ Project
Data Access In APIs Today
Data Access with DLINQ
DLinq For Relational Data
Architecture
Key Takeaways
Querying For Objects
When to Use LINQ to SQL?
Taking the Red Pill - How Can OTC Drug Brands Penetrate More HouseholdsTwentify
A look at the Canadian OTC drugs market, and examples on how market research can help brands in this market on differentiating themselves to get ahead of the competition.
How can OTC drug brands get ahead of the competition and differentiate themselves in the market using market research?
Generics Threats And Opportunities: Mounting an Effective Defense Strategy ...Eularis
After years of relatively easy blockbuster profits, worldwide respect and investment, and loyal customer bases, branded pharmaceutical companies are in trouble, increasingly vulnerable to the threats posed by the competition.
And who is that competition? It’s not other branded companies any more. Generics have emerged as the primary challenger to pharmaceutical industry success, offering a public hungry for medications and reduced costs exactly what they want and need. Generics have exploded in the last decades, and are poised for even bigger growth.
The situation is grim. It can seem like pharmaceutical companies have no recourse in the face of the lower prices and operating costs of the generics industry, and fortunes will only continue to fade.
But options do exist for pharmaceutical companies to mount an effective defense strategy against the threats posed by generics.
In this report, we examine some of these defensive strategies. We analyze the environment for pharmaceuticals today, as well as the generic industry as a whole.
We describe the pros and cons of legal defensive strategies, as well as opportunities to expand the revenue-generating product life cycle into reformulations and over-the-counter medications.
We look at pricing strategies, as well as company organizational changes as part of an integrated defense strategy.
And to help companies make tough decisions about the best defense, we examine powerful analytics techniques and case studies.
Object Relational Mapping with LINQ To SQLShahriar Hyder
OR Impedance Mismatch
Object Relational Mapping
The LINQ Project
Data Access In APIs Today
Data Access with DLINQ
DLinq For Relational Data
Architecture
Key Takeaways
Querying For Objects
When to Use LINQ to SQL?
NutrEvent 2011: Which Strategies to Run your Business With or Without A ClaimHMT18
Peter Wennstrom presented alongside Kirsten Brandt from University of Newcastle, Isabelle Schaller from Kraft and Christophe Ripoll from Naturalpha on Which Strategies to Run your Business with or without a claim?
The session was a part of the NutrEvent Conference hosted by the EBD Group on 16 June 2011 in Lille, France.
Empowering patients and health professionals through digital contentVanksen
From the innovations developed by international laboratories (use of AI and machine learning, biopharma, digital health…) to the latest international reforms designed to widen the access to care, all arrows point to the same direction: health has become an increasingly important topic, and even more so since the pandemic.
Vanksen’s experts zoomed in to try and understand the ways in which digital levers can empower pharma players around the world.
Experience taught us that marketing and communication have different rules if you are the CDO or CMO of a European lab. It is strictly forbidden to target patient audiences with content advertising subscription medication. So, what can they do?
https://www.vanksen.com/en/insights/empowering-patients-health-professionals-through-digital-content
The Digital Treatment - Digital Marketing Strategies - Ireland - Healthcare I...Promozoo Limited
In 2011, Promozoo published our first edition of the ‘PMI Digital Masterclass – A Guide to starting a Pharma Digital Marketing Campaign’. It proved very popular with professionals working in these specialised and heavily regulated industries.
Digital technology has changed a lot since then, and continues to change at such a fast pace, we decided it was time to update our initial edition with a new version for 2014. This new edition introduces new digital communication methods and strategies which have emerged over the past 2 years, and it is entitled ‘THE DIGITAL TREATMENT – HOW TO START A DIGITAL CAMPAIGN IN THE HEALTHCARE AND PHARMACEUTICAL INDUSTRIES’.
This new guide gives a starting structure to a digital marketing framework and is specifically created for Healthcare marketers, sales teams and senior management.
Although not always easy to put into practice, effective marketing is fairly straightforward if you possess a strong understanding of the core principles and can effectively work with your business partners. Marketing healthcare adds layers of complexities and complications that take time to fully understand. I hope this slide deck will help you navigate our industry just a little bit more easily.
Highlights From 7th Medical Science Liaison/MSL ConferenceExL Pharma
Current trends, issues and challenges facing MSL's in the pharmaceutical industry. Presented at the 7th MSL Best Practices conference, April, 2010. For further information, please visit www.exlpharma.com
2. “ With EFSA’s negative ruling on health claims, is your business going down?” Question to HMT from UK Journalist
3.
4. 1.The disconnect between health claims and consumers 2. The clash between basic communication rules and health claims 3. The impact on research, development and innovation. 5. The way forward for your brand – with or without health claims How to apply a brand led health claims strategy
13. So how can you communicate successfully to a consumer who doesn´t care, doesn´t trust, doesn´t undestand and most of all doesn´t have time to listen to you?
15. 2. The clash between basic communication rules and health claims
16. Why your brand is your most important asset. Because first impressions last…
17.
18. Your brand is the ‘space’ you occupy in the mind of the consumer That space is your starting point!
19. Brand stems from the Nordic word ”Brander” meaning to burn a mark.
20. 3. The impact on research, development and innovation
21.
22.
23. And this was also good news Great taste with no nasties..
24. But this was not what you nor anybody else expected from Coke..so it failed. If you want vitamins and minerals there are other more trusted choices… like Vitamin Water eg.
25. 5. The way forward for your brand – with or without claims. And the impact on research, development and innovation
34. Experts in helping brands respond to changing attitudes in nutrition, health and wellness. We work around the globe (25 countries in 2009) Specialise in brand positioning and product innovation / renovation in food, ingredients and pharmaceuticals. We are global implementation partners to HealthFocus Peter Wennstr ö m The Four Factors TM Brand Analysis System Food & Health Marketing Handbook Who are we?
35. What we do: Better targeted brands, faster to market! (and optimise effort and investment) We can improve your performance! And then make sure you stay on target! By getting the fundamentals right!
Technology stakeholders The ones motivated by tehcnology. This group puts funcitonal before food and will see the products in a medical context.
HealthFocus®Segment : Healers Lifestyle stakeholders The people who will be first to try out new benefits. This is a group who will Support the concept of functional foods and health-enhancing foods of all types provided that they work in the context of their lives and support their identity of being a front-runner HealthFocus®Segment : Disciples, Investors, Managers
Mass market stakeholders Will only be motivated by food benefits and they will wait until functional foods is clearly estabilshed in a normal food context. The health aspect is firmly secondary to the food. HealthFocus®Segment : Investors Managers, Strugglers, Unmotivated